These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21070209)

  • 1. Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseases.
    Moy JN; Scharenberg AM; Stein MR; Suez D; Roberts RL; Levy RJ; Ballow M; Fasano MB; Dash CH; Leach SJ
    Clin Exp Immunol; 2010 Dec; 162(3):510-5. PubMed ID: 21070209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of Gammaplex(®) 5% in children and adolescents with primary immunodeficiency diseases.
    Melamed IR; Gupta S; Stratford Bobbitt M; Hyland N; Moy JN
    Clin Exp Immunol; 2016 May; 184(2):228-36. PubMed ID: 26696596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex
    Wasserman RL; Melamed IR; Stein MR; Jolles S; Norton M; Moy JN;
    J Clin Immunol; 2017 Apr; 37(3):301-310. PubMed ID: 28316003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of Gammaplex® in idiopathic thrombocytopenic purpura (ClinicalTrials.gov--NCT00504075).
    Dash CH; Gillanders KR; Stratford Bobbitt ME; Gascoigne EW; Leach SJ
    PLoS One; 2014; 9(6):e96600. PubMed ID: 24892422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency.
    Krivan G; Chernyshova L; Kostyuchenko L; Lange A; Nyul Z; Derfalvi B; Musial J; Bellon A; Kappler M; Sadoun A; Bernatowska E
    J Clin Immunol; 2017 Aug; 37(6):539-547. PubMed ID: 28711959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.
    Suez D; Stein M; Gupta S; Hussain I; Melamed I; Paris K; Darter A; Bourgeois C; Fritsch S; Leibl H; McCoy B; Gelmont D; Yel L
    J Clin Immunol; 2016 Oct; 36(7):700-12. PubMed ID: 27582171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.
    Wasserman RL; Church JA; Stein M; Moy J; White M; Strausbaugh S; Schroeder H; Ballow M; Harris J; Melamed I; Elkayam D; Lumry W; Suez D; Rehman SM
    J Clin Immunol; 2012 Aug; 32(4):663-9. PubMed ID: 22392046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation.
    Kreuz W; Erdös M; Rossi P; Bernatowska E; Espanol T; Maródi L
    Clin Exp Immunol; 2010 Sep; 161(3):512-7. PubMed ID: 20550545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.
    Hagan JB; Fasano MB; Spector S; Wasserman RL; Melamed I; Rojavin MA; Zenker O; Orange JS
    J Clin Immunol; 2010 Sep; 30(5):734-45. PubMed ID: 20454851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
    Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
    Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
    Björkander J; Nikoskelainen J; Leibl H; Lanbeck P; Wallvik J; Lumio JT; Braconier JH; Pavlova BG; Birthistle K; Engl W; Walter S; Ehrlich HJ
    Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases.
    Ochs HD; Melamed I; Borte M; Moy JN; Pyringer B; D Kobayashi AL; Knutsen AP; Smits W; Pituch-Noworolska A; Kobayashi RH
    Immunotherapy; 2018 Oct; 10(14):1193-1202. PubMed ID: 30088423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
    Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
    Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gammaplex
    Wasserman RL
    Immunotherapy; 2017 Oct; 9(13):1071-1088. PubMed ID: 29032734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
    Jolles S; Rojavin MA; Lawo JP; Nelson R; Wasserman RL; Borte M; Tortorici MA; Imai K; Kanegane H
    J Clin Immunol; 2018 Nov; 38(8):864-875. PubMed ID: 30415311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.
    Stein MR; Nelson RP; Church JA; Wasserman RL; Borte M; Vermylen C; Bichler J;
    J Clin Immunol; 2009 Jan; 29(1):137-44. PubMed ID: 18814020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.
    Dorsey MJ; Ho V; Mabudian M; Soler-Palacín P; Domínguez-Pinilla N; Rishi R; Rishi R; Wong D; Rojavin M; Hubsch A; Berger M
    J Clin Immunol; 2014 Oct; 34(7):804-12. PubMed ID: 24981039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
    Wasserman RL; Melamed I; Stein MR; Engl W; Sharkhawy M; Leibl H; Puck J; Rubinstein A; Kobrynski L; Gupta S; Grant AJ; Ratnayake A; Richmond WG; Church J; Yel L; Gelmont D
    J Clin Immunol; 2016 Aug; 36(6):571-82. PubMed ID: 27220317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease.
    Kriván G; Königs Ch; Bernatowska E; Salama A; Wartenberg-Demand A; Sonnenburg C; Linde R
    Vox Sang; 2015 Oct; 109(3):248-56. PubMed ID: 25953213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
    McCormack PL
    BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.